<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04935879</url>
  </required_header>
  <id_info>
    <org_study_id>GBT2104-131</org_study_id>
    <secondary_id>2020-005286-13</secondary_id>
    <secondary_id>LBCTR2021054791</secondary_id>
    <nct_id>NCT04935879</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Blood Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Blood Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor,&#xD;
      in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and&#xD;
      adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will&#xD;
      be randomized to receive inclacumab or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants will be administered inclacumab or placebo intravenous (IV) every 12&#xD;
      weeks.&#xD;
&#xD;
      The total duration of treatment for each participant will be 48 weeks.&#xD;
&#xD;
      Participants that complete the study through Week 48 will be provided the opportunity to&#xD;
      enroll in an open-label extension (OLE) study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 26, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of VOCs during the 48-week treatment period.</measure>
    <time_frame>Day 1- Week 48</time_frame>
    <description>A VOC is defined as an acute episode of pain that:&#xD;
has no medically determined cause other than a vaso-occlusive event, and&#xD;
results in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), or results in a remote contact with a healthcare provider; and&#xD;
requires parenteral narcotic agents, parenteral non-steroidal anti-inflammatoroy drugs (NSAIDS), or an increase in treatment with oral narcotics.&#xD;
Complicated VOCs of acute chest syndrome (ACS), hepatic sequestration, splenic sequestration, and priapism that meet the requirements listed above will be included in the primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first VOC during the 48-week treatment period.</measure>
    <time_frame>Day 1- Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to second VOC during the 48-week treatment period Efficacy.</measure>
    <time_frame>Day 1- Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with no VOCs during the 48-week treatment period.</measure>
    <time_frame>Day 1- Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of VOCs that required admission to a healthcare facility and treatment with parenteral pain medication during the 48-week treatment period.</measure>
    <time_frame>Day 1- Week 48</time_frame>
    <description>Admission includes: (a) A hospital admission, or (b) An admission to an emergency room, observation unit, or infusion center for ≥ 12 hours, or (c) 2 visits to an emergency room, observation unit, or infusion center over a 72-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of inpatient hospitalization for a VOC during the 48-week treatment period.</measure>
    <time_frame>Day 1- Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs).</measure>
    <time_frame>Day 1- Week 48</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>PD parameter (P-selectin inhibition)</measure>
    <time_frame>Day 1- Week 48</time_frame>
    <description>To characterize the pharmacodynamics (PD) (P-selectin inhibition) of inclacumab at 30 mg/kg</description>
  </other_outcome>
  <other_outcome>
    <measure>PD parameter (Platelet Leukocyte Aggregation)</measure>
    <time_frame>Day 1- Week 48</time_frame>
    <description>To characterize the pharmacodynamics (PD) (PLA) of inclacumab at 30 mg/kg</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Vaso-occlusive Pain Episode in Sickle Cell Disease</condition>
  <condition>Vaso-occlusive Crisis</condition>
  <arm_group>
    <arm_group_label>inclacumab, 30 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inclacumab 30 mg/kg administered IV every 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo administered IV every 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inclacumab</intervention_name>
    <description>Inclacumab will be supplied in single use 10 mL vials at a concentration of 50 mg/mL. One vial contains 500 mg of inclacumab. This is a liquid concentrate for IV infusion.</description>
    <arm_group_label>inclacumab, 30 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be supplied in single use 10 mL vials containing the same ingredients without the active drug. Placebo will be prepared as a liquid concentrate for IV infusion and administered in the same manner as active study drug</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant has a confirmed diagnosis of SCD (HbSS, HbSC, HbSB0 thalassemia, or HbSB+&#xD;
             thalassemia genotype).&#xD;
&#xD;
             Documentation of SCD genotype is required and may be based on documented history of&#xD;
             laboratory testing or confirmed by laboratory testing during Screening.&#xD;
&#xD;
          2. Participant is male or female, ≥ 12 years of age at the time of informed consent.&#xD;
&#xD;
          3. Participant has experienced between 2 and 10 VOCs within the 12 months prior to the&#xD;
             Screening Visit as determined by documented medical history. A prior VOC is defined as&#xD;
             an acute episode of pain which:&#xD;
&#xD;
               -  Has no medically determined cause other than a vaso-occlusive event, and&#xD;
&#xD;
               -  Results in a visit to a medical facility (hospital, emergency department, urgent&#xD;
                  care center, outpatient clinic, or infusion center) or results in a remote&#xD;
                  contact with a healthcare provider; and&#xD;
&#xD;
               -  Requires parenteral narcotic agents, parenteral nonsteroidal anti- inflammatory&#xD;
                  drugs (NSAIDs), or an increase in treatment with oral narcotics.&#xD;
&#xD;
          4. Participants receiving erythropoiesis-stimulating agents (ESA, e.g., erythropoietin&#xD;
             [EPO]) must be on a stable dose for at least 90 days prior to the Screening Visit and&#xD;
             expected to continue with the stabilized regimen throughout the course of the study.&#xD;
&#xD;
          5. Participants receiving hydroxyurea (HU), L-glutamine, or voxelotor (Oxbryta®) must be&#xD;
             on a stable dose for at least 30 days prior to the Screening Visit and expected to&#xD;
             continue with the stabilized regimen throughout the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant is receiving regularly scheduled red blood cell (RBC) transfusion therapy&#xD;
             (also termed chronic, prophylactic, or preventative transfusion).&#xD;
&#xD;
          2. Participant is taking or has received crizanlizumab (ADAKVEO®) within 90 days prior to&#xD;
             the Screening Visit&#xD;
&#xD;
          3. Participant weighs &gt; 133 kg (292 lbs.).&#xD;
&#xD;
        Other protocol-defined Inclusion/Exclusion may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carolyn Hoppe, MD</last_name>
    <phone>650-822-8728</phone>
    <email>choppe@gbt.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eleanor Sales</last_name>
    <email>esales@gbt.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of South Alabama Children's and Women's Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Williams</last_name>
      <phone>251-405-5115</phone>
      <email>jgwilliams@health.southalabama.edu</email>
    </contact>
    <investigator>
      <last_name>Preethi Marri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol D'Ann Pierce, RN</last_name>
      <phone>501-364-4440</phone>
      <email>piercecarold@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Carolyn Suzanne Saccente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma Gonzalez, BS, CCRP</last_name>
      <phone>813-259-8813</phone>
      <email>egonzal2@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Juan Rico, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Scottish Rite Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Sanders</last_name>
      <phone>404-785-0305</phone>
      <email>amanda.sanders2@choa.org</email>
    </contact>
    <investigator>
      <last_name>Robert C Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taif Hassan</last_name>
      <phone>312-996-9052</phone>
      <email>tohassan@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Santosh Saraf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Jolley</last_name>
      <phone>671-525-7585</phone>
      <email>kljolley@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Maureen Achebe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bre'Anna Simpson</last_name>
      <phone>734-615-4630</phone>
      <email>sbreanna@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Ghada Abusin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabahete Zegiraj</last_name>
      <phone>718-918-6973</phone>
      <email>zeqirajs@nychhc.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Rivlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lindsey Muller, MSc</last_name>
      <phone>919-684-3543</phone>
      <email>lindsey.muller@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Nirmish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gail Fortner</last_name>
      <email>gail.fortner@stjude.org</email>
    </contact>
    <investigator>
      <last_name>Jeremie Estepp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nini Hospital</name>
      <address>
        <city>Tripoli</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamleh Ibrahim</last_name>
      <phone>96170500375</phone>
      <email>kamleh.ibrahim@hopitalnini.com</email>
    </contact>
    <investigator>
      <last_name>Adlette Inati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Lebanon</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.gbt.com/</url>
    <description>Global Blood Therapeutics (GBT) website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blood disorders</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>red blood cells</keyword>
  <keyword>sickle-like shape</keyword>
  <keyword>mutation in hemoglobin gene</keyword>
  <keyword>sickle-cell trait</keyword>
  <keyword>sickle-cell crisis</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>SCD</keyword>
  <keyword>Vaso-occlusive Crises</keyword>
  <keyword>VOC</keyword>
  <keyword>SCA</keyword>
  <keyword>RBCs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

